Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer (Abstracted from N Engl J Med 2019;381:2391–2402) The standard treatment for newly diagnosed advanced epithelial ovarian cancer involves cytoreductive surgery and platinum-taxane combination chemotherapy. Unfortunately, recurrence occurs in up to 85% of patients after completing this chemotherapy regimen. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Obstetrical & Gynecological Survey Wolters Kluwer Health

Loading next page...
 
/lp/wolters-kluwer-health/niraparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer-4WM85Uz72U

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
0029-7828
eISSN
1533-9866
DOI
10.1097/OGX.0000000000000756
Publisher site
See Article on Publisher Site

Abstract

(Abstracted from N Engl J Med 2019;381:2391–2402) The standard treatment for newly diagnosed advanced epithelial ovarian cancer involves cytoreductive surgery and platinum-taxane combination chemotherapy. Unfortunately, recurrence occurs in up to 85% of patients after completing this chemotherapy regimen.

Journal

Obstetrical & Gynecological SurveyWolters Kluwer Health

Published: Jan 1, 2020

There are no references for this article.